{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "64-year-old man with stage IV small cell lung cancer (SCLC).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Small cell lung cancer",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Patient received 3 lines of therapy over 1 year: 1) atezolizumab, carboplatin, and etoposide; 2) topotecan; 3) epirubicin, cyclophosphamide, and vincristine, but experienced progressive disease.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0004154",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0007127",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0015074",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0040424",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0014489",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0010320",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0205384",
              "label": "Disease progression",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Extensive somatostatin receptor (SSTR) positivity on PET of all tumor manifestations: extensive primary tumor with pleural metastases, multiple involved mediastinal lymph nodes and in the upper abdomen, and disseminated bone and brain metastases.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography",
              "body_part": "tumor manifestations",
              "modality": "PET",
              "finding": "Extensive somatostatin receptor positivity",
              "impression": "extensive primary tumor with pleural metastases, multiple involved mediastinal lymph nodes and in the upper abdomen, and disseminated bone and brain metastases."
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Patient deemed eligible for SSTR-directed radiopharmaceutical therapy (RPT).",
        "clinical_data": {}
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Patient received 7 cycles of SSTR-directed RPT with a mean intravenous activity of 7.34 GBq per cycle (range, 4.5-9.8 GBq) approximately every 4 weeks. Each cycle was administered after prior treatment with antiemetic and nephroprotective medication.",
        "clinical_data": {
          "medications": [
            {
              "drug": "antiemetic",
              "modality": "IV",
              "indication": "nausea"
            },
            {
              "drug": "nephroprotective medication",
              "modality": "IV",
              "indication": "kidney protection"
            }
          ],
          "procedures": [
            {
              "name": "Radiopharmaceutical therapy",
              "approach": "IV",
              "location": "systemic",
              "outcome": "treatment of cancer"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "After 2 therapy cycles, the patient presented with a partial response, with a significant reduction of the primary tumor, pleural metastases, and lymph node metastases and only minimal residual metabolic activity in the bone metastases.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C79.8",
              "label": "Secondary malignant neoplasm of other specified sites",
              "status": "active"
            }
          ],
          "imaging": [
            {
              "body_part": "T023517",
              "modality": "PET",
              "finding": "minimal residual metabolic activity",
              "impression": "partial response"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "After administration of cycle 4, [18F]FDG PET/CT still displayed an overall stable total tumor burden except for 2 new bone lesions in the lower spine.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography",
              "body_part": "Spine",
              "modality": "PET",
              "finding": "bone lesions",
              "date": null
            },
            {
              "type": "Computed tomography",
              "body_part": "Spine",
              "modality": "CT",
              "finding": "bone lesions",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "S",
        "clinical_data": {}
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient with stage IV small cell lung cancer (SCLC) experienced progressive disease after receiving 3 lines of therapy over 1 year: atezolizumab, carboplatin, and etoposide; topotecan; epirubicin, cyclophosphamide, and vincristine.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0004154",
            "C0007127",
            "C0015074",
            "C0040424",
            "C0014489",
            "C0010320"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Following disease progression after multiple lines of therapy, PET imaging revealed extensive somatostatin receptor (SSTR) positivity of all tumor manifestations: extensive primary tumor with pleural metastases, multiple involved mediastinal lymph nodes and in the upper abdomen, and disseminated bone and brain metastases."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Based on PET imaging findings of extensive SSTR positivity, the patient was deemed eligible for SSTR-directed radiopharmaceutical therapy (RPT)."
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient initiated SSTR-directed RPT.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Patient received 7 cycles of SSTR-directed RPT with a mean intravenous activity of 7.34 GBq per cycle (range, 4.5-9.8 GBq) approximately every 4 weeks. Each cycle was administered after prior treatment with antiemetic and nephroprotective medication. After 2 therapy cycles, the patient presented with a partial response, with a significant reduction of the primary tumor, pleural metastases, and lymph node metastases and only minimal residual metabolic activity in the bone metastases.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "other",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Following initial partial response after 2 cycles of SSTR-directed RPT, [18F]FDG PET/CT after cycle 4 displayed an overall stable total tumor burden except for 2 new bone lesions in the lower spine.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "After administration of cycle 4, [18F]FDG PET/CT still displayed an overall stable total tumor burden except for 2 new bone lesions in the lower spine."
      }
    }
  ]
}